SG11201811704SA - Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders - Google Patents

Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders

Info

Publication number
SG11201811704SA
SG11201811704SA SG11201811704SA SG11201811704SA SG11201811704SA SG 11201811704S A SG11201811704S A SG 11201811704SA SG 11201811704S A SG11201811704S A SG 11201811704SA SG 11201811704S A SG11201811704S A SG 11201811704SA SG 11201811704S A SG11201811704S A SG 11201811704SA
Authority
SG
Singapore
Prior art keywords
international
biogen
cambridge
rule
binney
Prior art date
Application number
SG11201811704SA
Inventor
Diego Cadavid
Lei Xu
Lin Xu
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of SG11201811704SA publication Critical patent/SG11201811704SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111101111 0 DOI HIM 011101 0 0111111 01110011H111111111111111111111111111111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/013714 Al 18 January 2018 (18.01.2018) WI P0 I P C T (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, A61K 39/395 (2006.01) G01N 33/50 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, PCT/US2017/041757 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 12 July 2017 (12.07.2017) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 62/362,032 13 July 2016 (13.07.2016) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/394,094 13 September 2016 (13.09.2016) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/412,582 25 October 2016 (25.10.2016) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 62/486,217 17 April 2017 (17.04.2017) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 62/512,510 30 May 2017 (30.05.2017) US TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (71) Applicant: BIOGEN MA INC. [US/US]; 225 Binney St, Cambridge, MA 02142 (US). Declarations under Rule 4.17: (72) Inventors: CADAVID, Diego; c/o Biogen MA Inc., 225 — as to applicant's entitlement to apply for and be granted a Binney Street, Cambridge, MA 02142 (US). XU, Lei; c/o patent (Rule 4.17(0 Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 — as to the applicant's entitlement to claim the priority of the (US). XU, Lin; c/o Biogen MA Inc., 225 Binney Street, earlier application (Rule 4.17(iii)) Cambridge, MA 02142 (US). Published: (74) Agent: BRENNAN, Jack et al.; Fish & Richardson P.C., — with international search report (Art. 21(3)) P.O. Box 1022, Minneapolis, MN 55440-1022 (US). — with sequence listing part of description (Rule 5.2(a)) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, Title: DOSAGE REGIMENS OF LINGO-1 ANTAGONISTS AND USES FOR TREATMENT OF DEMYELINATING = (54) DISORDERS End of End of study/ treatment follow-up AON onset Baseline Trragulaggi4 whe visit visit Day-2b Day 1 W4 WS W12 W16 W20 W24 W32 Screen 1 ,--- : (pretreatrn 4 ent) 1-1 cu 0 3-5 days IV 71- steroidsa 1-1 IN C 4 \") 1-1 aFor participants with AON who had not been already treated. 0 --.... ,-, © ei I. I (57) : Dosage regimens, methods, compositions and kits are described herein useful for detecting and/or treating a CNS demyelinating disease.
SG11201811704SA 2016-07-13 2017-07-12 Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders SG11201811704SA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662362032P 2016-07-13 2016-07-13
US201662394094P 2016-09-13 2016-09-13
US201662412582P 2016-10-25 2016-10-25
US201762486217P 2017-04-17 2017-04-17
US201762512510P 2017-05-30 2017-05-30
PCT/US2017/041757 WO2018013714A1 (en) 2016-07-13 2017-07-12 Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders

Publications (1)

Publication Number Publication Date
SG11201811704SA true SG11201811704SA (en) 2019-01-30

Family

ID=59388180

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811704SA SG11201811704SA (en) 2016-07-13 2017-07-12 Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders

Country Status (16)

Country Link
US (2) US20200031924A1 (en)
EP (1) EP3484512A1 (en)
JP (1) JP7149257B2 (en)
KR (1) KR20190039134A (en)
CN (1) CN109862911A (en)
AU (1) AU2017297404A1 (en)
BR (1) BR112019000630A2 (en)
CA (1) CA3030745A1 (en)
CL (1) CL2019000027A1 (en)
CO (1) CO2019001116A2 (en)
IL (1) IL264139A (en)
MA (1) MA45668A (en)
MX (1) MX2019000327A (en)
PH (1) PH12019500075A1 (en)
SG (1) SG11201811704SA (en)
WO (1) WO2018013714A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3133072A1 (en) * 2019-03-11 2020-09-17 Biogen Ma Inc. Pharmaceutical compositions containing anti-lingo-1 antibodies
US12226460B2 (en) 2023-03-17 2025-02-18 Biome-ase Research, LLC Enzymatic methods for treating neurodegenerative disorders
CN116549632B (en) * 2023-03-28 2024-09-10 中国人民解放军军事科学院军事医学研究院 New application of anti-Lingo-1 antibody Opicinumab and medicine for new application
CN116740064B (en) * 2023-08-14 2023-10-20 山东奥洛瑞医疗科技有限公司 Nuclear magnetic resonance tumor region extraction method

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimeric monoclonal antibody and its production method
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (en) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド Method for producing specific binding pair members
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
DK1279731T3 (en) 1991-03-01 2007-09-24 Dyax Corp Process for the development of binding mini-proteins
ES2315612T3 (en) 1991-04-10 2009-04-01 The Scripps Research Institute GENOTECAS OF HETERODYMERIC RECEPTORS USING PHAGEMIDS.
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
PT656946E (en) 1992-08-21 2001-12-28 Univ Bruxelles IMMUNOGLOBULINS FOR LIGHT CHAINS
PT669986E (en) 1992-11-13 2003-08-29 Idec Pharma Corp ALTERED DOMINANT SELECTION MARKER SEQUENCE AND INTRONONIC INSERT STRATEGIES FOR IMPROVING GENERIC PRODUCT EXPRESSION AND EXPRESSION VECTOR SYSTEMS THAT UNDERSTAND IT
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
DK0682529T4 (en) 1993-02-09 2006-05-15 Biogen Idec Inc Antibody for the treatment of insulin-requiring diabetes
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
RO120148B1 (en) 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Vector system and method for integrating a dna fragment in the mammalian cells genome
IL151781A0 (en) 2000-03-16 2003-04-10 Genetica Inc Methods and compositions for rna interference
ATE459651T1 (en) 2001-08-10 2010-03-15 Univ Aberdeen ANTIGEN BINDING DOMAIN FROM FISH
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
AU2003234336A1 (en) 2002-05-03 2003-11-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing sirnas
DE60328214D1 (en) 2002-08-12 2009-08-13 New England Biolabs Inc METHOD AND COMPOSITIONS IN CONNECTION WITH GEN-SILENCING
ATE479754T1 (en) 2003-03-19 2010-09-15 Biogen Idec Inc NOGO RECEPTOR BINDING PROTEIN
WO2006002437A2 (en) 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
CN1972707B (en) * 2004-06-24 2014-12-03 比奥根艾迪克Ma公司 Treatment of conditions involving demyelination
EP2084190B1 (en) * 2006-11-17 2011-03-23 Novartis AG Lingo binding molecules and pharmaceutical use thereof
PT2068887E (en) * 2007-01-09 2014-06-23 Biogen Idec Inc Sp35 antibodies and uses thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101980603A (en) * 2007-10-11 2011-02-23 比奥根艾迪克Ma公司 Use of LINGO-1 and TrkB antagonists
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE
EP2672823B1 (en) 2011-02-07 2016-08-24 Biogen MA Inc. S1p modulating agents
EP2906240A2 (en) * 2012-10-09 2015-08-19 Biogen MA Inc. Combination therapies and uses for treatment of demyelinating disorders
MX2017009038A (en) * 2015-01-08 2017-10-25 Biogen Ma Inc Lingo-1 antagonists and uses for treatment of demyelinating disorders.

Also Published As

Publication number Publication date
WO2018013714A1 (en) 2018-01-18
JP7149257B2 (en) 2022-10-06
US20200031924A1 (en) 2020-01-30
US20210403556A1 (en) 2021-12-30
JP2019524731A (en) 2019-09-05
BR112019000630A2 (en) 2019-07-09
MX2019000327A (en) 2019-04-11
PH12019500075A1 (en) 2019-07-08
CA3030745A1 (en) 2018-01-18
CL2019000027A1 (en) 2019-05-24
MA45668A (en) 2019-05-22
IL264139A (en) 2019-02-28
EP3484512A1 (en) 2019-05-22
CO2019001116A2 (en) 2019-02-19
KR20190039134A (en) 2019-04-10
CN109862911A (en) 2019-06-07
AU2017297404A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
SG11201809082WA (en) Nlrp3 modulators
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201811432WA (en) Rna for cancer therapy
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201805001UA (en) Method of treating influenza a
SG11201901249YA (en) Aza-indazole compounds for use in tendon and/or ligament injuries
SG11201811704SA (en) Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
SG11201910183SA (en) C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof